AIM: The role of CYP1A in the protection of aristolochic acid (AA)I-induced nephrotoxicity has been suggested. In the present study we investigated the effects of beta-naphthoflavone (BNF), a non-carcinogen CYP1A inducer, on AAI-induced kidney injury. METHODS: Mice were pretreated with 80 mg/kg BNF by daily intraperitoneal injection (ip) for 3 days followed by a single ip of 10 mg/kg AAI. AAI and its major metabolites in blood, liver and kidney, the expression of CYP1A1 and CYP1A2 in microsomes of liver and kidney, as well as the nephrotoxicity were evaluated. RESULTS: BNF pretreatment prevented AAI-induced renal damage by facilitating the disposal of AAI in liver. BNF pretreatment induced the expression of CYP1A1 in both liver and kidney; but the induction of CYP1A2 was only observed in liver. CONCLUSION: BNF prevents AAI-induced kidney toxicity primarily through CYP1A induction.
AIM: The role of CYP1A in the protection of aristolochic acid (AA)I-induced nephrotoxicity has been suggested. In the present study we investigated the effects of beta-naphthoflavone (BNF), a non-carcinogen CYP1A inducer, on AAI-induced kidney injury. METHODS:Mice were pretreated with 80 mg/kg BNF by daily intraperitoneal injection (ip) for 3 days followed by a single ip of 10 mg/kg AAI. AAI and its major metabolites in blood, liver and kidney, the expression of CYP1A1 and CYP1A2 in microsomes of liver and kidney, as well as the nephrotoxicity were evaluated. RESULTS:BNF pretreatment prevented AAI-induced renal damage by facilitating the disposal of AAI in liver. BNF pretreatment induced the expression of CYP1A1 in both liver and kidney; but the induction of CYP1A2 was only observed in liver. CONCLUSION:BNF prevents AAI-induced kidney toxicity primarily through CYP1A induction.
Authors: Frédéric D Debelle; Joëlle L Nortier; Eric G De Prez; Christian H Garbar; Anne R Vienne; Isabelle J Salmon; Monique M Deschodt-Lanckman; Jean-Louis Vanherweghem Journal: J Am Soc Nephrol Date: 2002-02 Impact factor: 10.121
Authors: J L Nortier; M C Martinez; H H Schmeiser; V M Arlt; C A Bieler; M Petein; M F Depierreux; L De Pauw; D Abramowicz; P Vereerstraeten; J L Vanherweghem Journal: N Engl J Med Date: 2000-06-08 Impact factor: 91.245
Authors: Frédéric D Debelle; Joëlle L Nortier; Cécile P Husson; Eric G De Prez; Anne R Vienne; Katja Rombaut; Isabelle J Salmon; Monique M Deschodt-Lanckman; Jean-Louis Vanherweghem Journal: Kidney Int Date: 2004-11 Impact factor: 10.612
Authors: Jana Sistkova; Jiri Hudecek; Petr Hodek; Eva Frei; Heinz H Schmeiser; Marie Stiborova Journal: Neuro Endocrinol Lett Date: 2008-10 Impact factor: 0.765
Authors: Shigeyuki Uno; Timothy P Dalton; Sandrine Derkenne; Christine P Curran; Marian L Miller; Howard G Shertzer; Daniel W Nebert Journal: Mol Pharmacol Date: 2004-05 Impact factor: 4.436
Authors: Y Xiao; M Ge; X Xue; C Wang; H Wang; X Wu; L Li; L Liu; X Qi; Y Zhang; Y Li; H Luo; T Xie; J Gu; J Ren Journal: Kidney Int Date: 2008-03-26 Impact factor: 10.612
Authors: Xiang Xue; Matthew Taylor; Erik Anderson; Cathy Hao; Aijuan Qu; Joel K Greenson; Ellen M Zimmermann; Frank J Gonzalez; Yatrik M Shah Journal: Cancer Res Date: 2012-03-14 Impact factor: 12.701
Authors: Thomas A Rosenquist; Heidi J Einolf; Kathleen G Dickman; Lai Wang; Amanda Smith; Arthur P Grollman Journal: Drug Metab Dispos Date: 2010-02-17 Impact factor: 3.922